Licensing deals

Glowing puzzle piece fitting into puzzle
Biotech

Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
James Waldron Oct 24, 2025 9:15am
gold coins and bars

Takeda strikes Innovent pact worth up to $11.4B

Oct 22, 2025 9:15am
graphic art of a right hand signing something

Hansoh, Chugai ink separate and lucrative licensing agreements

Oct 17, 2025 11:04am
Two businessmen pushing giant puzzle pieces together as the sun sets behind them

Dianthus offers up to $1B for China biotech’s autoimmune asset

Oct 16, 2025 10:57am
arrow target quiver aim shoot ammo

AstraZeneca pens fresh IBD collab with Immunai worth $85M

Oct 16, 2025 9:00am
antibody antibody-drug conjugate antibody drug conjugate ADC

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am